drugset / Trial / NCT01184898
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
Completed
36 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
University of Pennsylvania · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the addition of Sirolimus (rapamycin) to standard chemotherapy for the treatment of patients with high risk acute myelogenous leukemia (AML). Cancer cells taken from the patients will be studied in the laboratory to see if rapamycin is affecting the mTOR pathway in the cells and if this effect is correlated with how well patients respond to the therapy.
Timeline
- Start
- 2010-07
- Primary completion
- 2012-01
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 4 mg | Oral |
| Background | Cytarabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Mitoxantrone | Small molecule | 8 mg/m2 | Intravenous |